Ignite Creation Date:
2024-05-06 @ 4:06 PM
Last Modification Date:
2024-10-26 @ 2:03 PM
Study NCT ID:
NCT04872790
Status:
RECRUITING
Last Update Posted:
2023-12-20
First Post:
2021-03-19
Brief Title:
Venetoclax Dasatinib Prednisone Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
Sponsor:
OHSU Knight Cancer Institute
Organization:
OHSU Knight Cancer Institute
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-09-02
Start Date Type:
ACTUAL
Primary Completion Date:
2025-06-02
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-06-02
Completion Date Type:
ESTIMATED
First Submit Date:
2021-03-19
First Submit QC Date:
May 3 2021
Study First Post Date:
2021-05-05
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-08-30
Last Update Post Date:
2023-12-20
Last Update Post Date Type:
ACTUAL